RESEARCHER PROFILE
Panagiotis Petrou
← Back to University of Nicosia
P
University of Nicosia
Panagiotis Petrou works in Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Healthcare Systems and Reforms, Healthcare Policy and Management, Economic and Financial Impacts of Cancer. Recorded institutional associations include University Medical Center Groningen, University of Groningen, University of Nicosia.
77Publications
667Citations
15H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
A systematic review and meta-analysis of vitamin D and calcium in preventing osteoporotic fractures
2020 · 48 citationsBurden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices
2021 · 37 citationsSingle-payer or a multipayer health system: a systematic literature review
2018 · 35 citationsIs it a Chimera? A systematic review of the economic evaluations of CAR-T cell therapy
2019 · 31 citationsTendering for pharmaceuticals as a reimbursement tool in the Cyprus Public Health Sector
2014 · 28 citationsA systematic review of the economic evaluations of Enzyme Replacement Therapy in Lysosomal Storage Diseases
2022 · 28 citationsAn Interrupted Time-Series Analysis to Assess Impact of Introduction of Co-Payment on Emergency Room Visits in Cyprus
2015 · 26 citationsThe 2019 introduction of the new National Healthcare System in Cyprus
2021 · 23 citationsCyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment
2015 · 21 citationsFailed Attempts to Reduce Inappropriate Laboratory Utilization in an Emergency Department Setting in Cyprus: Lessons Learned
2015 · 19 citationsCrisis as a serendipity for change in Cyprus' healthcare services
2015 · 18 citationsCost–effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus
2014 · 18 citationsMethodological considerations in injury burden of disease studies across Europe: a systematic literature review
2022 · 17 citationsA Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations
2013 · 16 citationsA pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer
2014 · 15 citationsA Comprehensive Molecular Epidemiological Analysis of SARS-CoV-2 Infection in Cyprus from April 2020 to January 2021: Evidence of a Highly Polyphyletic and Evolving Epidemic
2021 · 15 citationsPrice Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market
2015 · 14 citationsLong-term effect of tendering on prices of branded pharmaceutical products
2015 · 14 citationsCo-payments for emergency department visits: a quasi-experimental study
2019 · 14 citationsHealthcare reforms in Cyprus 2013–2017: Does the crisis mark the end of the healthcare sector as we know it?
2017 · 13 citationsComparison of validation protocols for blood pressure measuring devices in children and adolescents
2022 · 13 citationsPharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective
2014 · 12 citationsCost-effectiveness analysis of axitinib through a probabilistic decision model
2015 · 11 citationsThe power of r – pharmaceutical sales decomposition in Cyprus public healthcare sector and determinants of drug expenditure evolution: any lessons learned?
2014 · 11 citationsBurden of disease attributable to risk factors in European countries: a scoping literature review
2023 · 11 citations
